Skip to main content
Opthea Ltd logo

Opthea Ltd — Investor Relations & Filings

Ticker · OPT ISIN · US68386J2087 LEI · 549300Q5FMFDLP46SF83 ASX Manufacturing
Open in API
Filings indexed 1,390 across all filing types
Latest filing 2013-11-28 AGM Information
Country AU Australia
Listing ASX OPT

About Opthea Ltd

https://opthea.com/

Opthea is a clinical-stage biopharmaceutical company focused on developing novel therapies for vision-threatening retinal diseases, particularly wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). The company's lead product candidate, sozinibercept, is a first-in-class biologic 'trap' inhibitor targeting Vascular Endothelial Growth Factors C and D (VEGF-C and VEGF-D). Sozinibercept is being developed for administration in combination with standard-of-care anti-VEGF-A therapies. This dual-pathway inhibition aims to deliver superior visual outcomes by more comprehensively blocking the mechanisms that contribute to disease progression, addressing the limitations of current treatments that only target VEGF-A. The therapy is being evaluated in late-stage pivotal clinical trials for wet AMD.

Recent filings

Filing Released Lang Actions
CEOs Address To Annual General Meeting 49 pages 1.4MB
AGM Information Classification · 95% confidence The document is titled 'ANNUAL GENERAL MEETING 29 NOVEMBER 2013' and contains a detailed presentation by the CEO and Managing Director of Circadian Technologies. It includes corporate snapshots, financials, status of key projects, business model, and expected milestones. The content is structured as a presentation given at the Annual General Meeting (AGM), focusing on company strategy, financial overview, and project updates. There is no indication that this is a full annual report (10-K) or an earnings release (ER). The document is a presentation material specifically prepared for the AGM event. Therefore, it fits the category of AGM Information (AGM-R). The document length (15,000 characters) and detailed content support this classification with high confidence.
2013-11-28 English
Results of Annual General Meeting 1 page 21.9KB
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a media release dated 29 November 2013, titled 'RESULTS OF ANNUAL GENERAL MEETING'. It reports the voting results of resolutions put to the AGM, including the adoption of the Remuneration Report and the withdrawal of a director re-election resolution. The text references the Corporations Act and ASX Listing Rule 3.13.2, which govern disclosure of voting results. The document is short (1142 characters) and focuses solely on the outcome of shareholder votes at the AGM, without containing the full AGM materials or detailed financial data. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2013-11-28 English
Phase 1b oncology trial completed 4 pages 374.7KB
Capital/Financing Update Classification · 90% confidence The document is an ASX and media release dated 27 November 2013 announcing the completion milestone in a Phase 1b oncology clinical study of VGX-100 with Avastin. It details clinical trial progress, safety results, and plans for Phase 2 studies. The content focuses on clinical trial updates and development milestones rather than financial results, regulatory filings, or management changes. There is no indication that this is a full financial report, audit report, earnings release, or regulatory filing. It is a corporate announcement about clinical trial progress and development milestones, which fits best under the category of Capital/Financing Update (CAP) as it relates to development progress that could impact financing and investment decisions. The document length is over 12,000 characters and contains substantive information, not just a brief announcement or link to a report, so it is not a Report Publication Announcement (RPA) or Regulatory Filing (RNS). Therefore, the most appropriate classification is CAP with high confidence.
2013-11-26 English
R&D Tax Incentive - Circadian To Receive Over $2.5m 2 pages 49.6KB
Capital/Financing Update Classification · 95% confidence The document is an ASX and media release dated 15 November 2013 announcing that Circadian Technologies expects to receive over $2.5 million from the Federal Government R&D Tax Incentive for its 2013 financial year R&D expenditure. It discusses expected future R&D expenditure and tax credits but does not contain financial statements, detailed financial results, or comprehensive report data. The document is a public announcement about a government incentive receipt and expected funding, not a financial report or detailed investor presentation. It is not a regulatory filing with officer certifications, nor is it a report publication announcement. The content fits best as a Capital/Financing Update (CAP) because it relates to funding and financial incentives impacting the company's capital resources.
2013-11-14 English
Opthea Signs Manufacturing Agreement 6 pages 484.0KB
Capital/Financing Update Classification · 95% confidence The document is an ASX and media release dated 30 Oct 2013 announcing that Circadian Technologies, through its subsidiary Opthea Pty Ltd, has signed a manufacturing agreement with DSM Pharmaceutical Products for the lead product OPT-302. The text includes detailed information about the agreement, the product, the disease it targets, and company background. It is a press release announcing a business development event rather than a financial report or regulatory filing. There are no financial statements, earnings data, or regulatory compliance content. The document is not a report itself but an announcement of a corporate event. Therefore, it fits best into the category of a Capital/Financing Update (CAP) as it relates to a significant business agreement impacting the company's product development and potential capital deployment. The document length (15,000 characters) and content confirm it is a full announcement rather than a brief notice or report publication announcement.
2013-10-29 English
Annual Report / Notice of AGM & Proxy Form 107 pages 6.7MB
AGM Information Classification · 100% confidence The document is titled 'Notice of Annual General Meeting and Explanatory Memorandum' for Circadian Technologies Limited, dated 29 November 2013. It includes details about the AGM such as date, time, location, agenda items including financial statements and reports, remuneration report resolution, re-election of a director, proxy instructions, voting entitlements, and explanatory notes. The document explicitly states it is a Notice of AGM and includes an explanatory memorandum to assist shareholders in voting. It does not contain the actual financial statements or reports but refers to the Annual Report being available separately. The document is about the meeting and materials shared for the AGM, not the full annual report or financial statements themselves. Therefore, it fits the category of AGM Information (AGM-R).
2013-10-27 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.